Cover Image
市場調查報告書

肝臟移植:開發平台分析

Liver Transplantation - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 251552
出版日期 內容資訊 英文 78 Pages
訂單完成後即時交付
價格
Back to Top
肝臟移植:開發平台分析 Liver Transplantation - Pipeline Review, H1 2016
出版日期: 2016年04月13日 內容資訊: 英文 78 Pages
簡介

肝臟移植是各種肝臟疾病的常見療法。肝臟與其他器官不同,具有獨特的再生及成長力。肝臟移植是將健康的肝臟取代受損或是患病的肝臟。有完全移植及部分移植二種。移植後免疫系統會視肝臟為異物而排斥。為此,患者可能會發生對新移植的肝臟完全排斥反應。因此必須同時給予免疫抑制劑。這些抑制劑可預防身體對外來的器官透過各種免疫反應的接受或排斥,來抑制器官的排斥以順利完成器官移植。

本報告提供肝臟移植的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關最新的新聞和發表及開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

目錄

簡介

  • 調查範圍

肝臟移植 概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • Astellas Pharma Inc.
  • Conatus Pharmaceuticals Inc.
  • Digna Biotech, S.L.
  • Dompe Farmaceutici S.p.A.
  • Isogenis, Inc.
  • RedHill Biopharma Ltd.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ABC-294640
  • cardiotrophin-1
  • Cell Therapy for Liver Transplantation
  • Cell Therapy for Liver Transplantation
  • Cell Therapy for Liver Transplantation
  • emricasan
  • Gene Therapy for High-Grade Glioma and Liver Transplantation
  • reparixin
  • tacrolimus ER - Drug Profile

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7906IDB

Summary

Global Markets Direct's, 'Liver Transplantation - Pipeline Review, H1 2016', provides an overview of the Liver Transplantation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Liver Transplantation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Transplantation and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Liver Transplantation
  • The report reviews pipeline therapeutics for Liver Transplantation by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Liver Transplantation therapeutics and enlists all their major and minor projects
  • The report assesses Liver Transplantation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Liver Transplantation

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Liver Transplantation
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Liver Transplantation pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Liver Transplantation Overview
  • Therapeutics Development
    • Pipeline Products for Liver Transplantation - Overview
    • Pipeline Products for Liver Transplantation - Comparative Analysis
  • Liver Transplantation - Therapeutics under Development by Companies
  • Liver Transplantation - Therapeutics under Investigation by Universities/Institutes
  • Liver Transplantation - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Liver Transplantation - Products under Development by Companies
  • Liver Transplantation - Products under Investigation by Universities/Institutes
  • Liver Transplantation - Companies Involved in Therapeutics Development
    • Astellas Pharma Inc.
    • Conatus Pharmaceuticals Inc.
    • Digna Biotech, S.L.
    • Dompe Farmaceutici S.p.A.
    • Novartis AG
    • RedHill Biopharma Ltd.
  • Liver Transplantation - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ABC-294640 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cardiotrophin-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy for Liver Transplantation - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy for Liver Transplantation - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • emricasan - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • everolimus - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FX-06 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for High-Grade Glioma and Liver Transplantation - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • reparixin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tacrolimus ER - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TR-002 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Liver Transplantation - Recent Pipeline Updates
  • Liver Transplantation - Dormant Projects
  • Liver Transplantation - Discontinued Products
  • Liver Transplantation - Product Development Milestones
    • Featured News & Press Releases
      • Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting
      • May 12, 2014: Conatus Pharmaceuticals Initiates Phase 2b Trial Targeting Fibrosis in Liver Transplant Recipients
      • Nov 02, 2013: Conatus Pharmaceuticals Presents Data Demonstrating Emricasan's Safety Profile at the AASLD Liver Meeting
      • Dec 04, 2012: Astellas Pharma Announces Acceptance Of US New Drug Application For Tacrolimus Extended Release Capsules
      • Oct 20, 2011: European Medicines Agency Agrees To Precautionary Recall Of Advagraf 0.5mg Capsule Batches
      • Jul 01, 2011: Astellas Introduces Advagraf In India
      • Mar 16, 2011: Digna Biotech And Biotecnol Receive Spanish Approval For Phase I Clinical Studies Of Cardiotrophin I
      • Feb 18, 2011: Astellas Introduces Advagraf in China-once daily administration, leading the new trend in immunosuppressive therapy after organ transplant
      • Oct 02, 2007: New Once-Daily Advagraf Launched Across Europe.
      • Jun 18, 2007: Advagraf Now Available in Germany and the UK as a Once-Daily Immunosuppressant in Organ Transplantation
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Liver Transplantation, H1 2016
  • Number of Products under Development for Liver Transplantation - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Liver Transplantation - Pipeline by Astellas Pharma Inc., H1 2016
  • Liver Transplantation - Pipeline by Conatus Pharmaceuticals Inc., H1 2016
  • Liver Transplantation - Pipeline by Digna Biotech, S.L., H1 2016
  • Liver Transplantation - Pipeline by Dompe Farmaceutici S.p.A., H1 2016
  • Liver Transplantation - Pipeline by Novartis AG, H1 2016
  • Liver Transplantation - Pipeline by RedHill Biopharma Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Liver Transplantation Therapeutics - Recent Pipeline Updates, H1 2016
  • Liver Transplantation - Dormant Projects, H1 2016
  • Liver Transplantation - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Liver Transplantation, H1 2016
  • Number of Products under Development for Liver Transplantation - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top